* = Guardant360 Liquid CDx is under review with Notified Body / EMA.
Product availability may vary depending on country / region.
1 Nogueiras-Álvarez R, Pérez Francisco I. Pharmacogenetics in oncology: a useful tool for individualizing drug therapy. Br J Clin Pharmacol. 2024;90(10):2483-2508. doi:10.1111/bcp.16181;
2. Safabakhsh P, Tolkunov D, Overstreet B, et al. HRD status prediction using a liquid biopsy assay in advanced solid tumors. J Clin Oncol. 2025;43(16 suppl):3074. doi:10.1200/JCO.2025.43.16_suppl.3074;
3. Tung L, Valouev A, Odegaard J, et al. Fusion epigenotyping using cell-free DNA methylation improves detection of actionable ALK fusions in non-small cell lung cancer. Abstract presented at: American Association for Cancer Research Annual Meeting; April 20, 2026; San Diego, CA. Abstract 1409.
Home Oncology Portfolio Partnerships European Policy
Please ask the booth Team.
Pharmacogenomics:
Optimize treatment
and reduce toxicity by identifying alleles.1
HRD Status:
Predict HRD status
to inform the use of PARP inhibitors
and platinum-based chemotherapies.2
Methylation-based ALK fusion detection:
Enhanced detection of ALK fusions in liquid biopsy to help inform use of ALK inhibitors.3